Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outpatient IV insulin

This article was originally published in The Gray Sheet

Executive Summary

CMS releases decision memo Dec. 23 ordering national non-coverage of outpatient intravenous insulin treatments, writing that the evidence does not support it as a reasonable and necessary service for diabetic Medicare patients. CMS opened a coverage analysis on the intermittent adjunct therapy last March (1"The Gray Sheet" March 30, 2009). Supporters claim the treatment can help prevent the onset of debilitating conditions and delay the need for more expensive therapies, such as dialysis (2"The Gray Sheet" May 4, 2009)
Advertisement

Related Content

IV Insulin Supporters Argue For Coverage On Basis Of Cost Effectiveness
CMS Exploring Coverage Of Outpatient Intravenous Insulin Treatments
CMS Exploring Coverage Of Outpatient Intravenous Insulin Treatments

Topics

Advertisement
UsernamePublicRestriction

Register

MT028336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel